Join the Capital Chapter for a webinar "Gene Therapy Payment Solutions - Background & Market Update" on Thursday, May 25th at 9:00 am EST. Our speaker is Wes Smith with EmsanaRx. Wes will discuss:
• What cell and gene therapies are, and why they’re so expensive
• Newly emerging funding and payment mechanisms
• Distinctive features of these new solutions
• Considerations when evaluating new solutions (specifically, for employers)
Wes Smith, FSA, CERA, MAAA
Analytics and Reporting
Wes Smith leads Analytics and Reporting for EmsanaRx. He works closely with internal and external stakeholders to help show and support EmsanaRx’s value, objectively and transparently, using data. As an actuary by trade, his true focus is problem solving. Combined with his passion for working with clients, he is able to leverage his technical expertise to help customers navigate ever increasing challenges in the pharmacy space.
Prior to joining EmsanaRx, Wes held numerous actuarial and consulting-focused roles across several healthcare organizations including Certilytics, Mercer, and Anthem. Wes is a Fellow of the Society of Actuaries (FSA), a Chartered Enterprise Risk Analyst (CERA), and a Member of the American Academy of Actuaries (MAAA). He is a graduate of Bellarmine University with degrees in Economics and Business Administration.
For information regarding sponsorship opportunities please visit the Chapter’s Sponsorship page or contact us at: firstname.lastname@example.org.